The Alpha-Lipoic Acid Derivative Sodium Zinc Dihydrolipoylhistidinate Reduces Chemotherapy-Induced Alopecia in a Rat Model: A Pilot Study

    April 2011 in “ Surgery today
    Satoshi Hagiwara, Tomohisa Uchida, Hironori Koga, Masafumi Ito, Fumitaka Yoshizumi, Masatsugu Moriyama, Seigo Kitano, Takayuki Noguchi
    Image of study
    TLDR A substance called sodium zinc dihydrolipoylhistidinate can significantly reduce hair loss caused by chemotherapy in rats.
    In a pilot study from 2011 involving 40 Wistar rats, the α-lipoic acid derivative sodium zinc dihydrolipoylhistidinate (DHLHZn) was shown to significantly reduce chemotherapy-induced alopecia. The rats were divided into four groups of 10, with one group acting as a control and the other three receiving cytosine arabinoside (AraC) to induce alopecia and different concentrations of DHLHZn (0%, 0.5%, or 1%) applied topically. The study found that rats treated with AraC and 0% DHLHZn experienced complete hair loss, while those treated with 0.5% or 1% DHLHZn had significantly less hair loss. Histological analysis indicated that DHLHZn treatment reduced inflammatory cell infiltration in hair follicles caused by AraC. The study suggests that DHLHZn could be a potential therapeutic agent for chemotherapy-induced alopecia, but further research is needed to confirm its effectiveness and understand its mechanisms of action.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 125 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 4 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    6 / 6 results